AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated activity in patients with recurrent GBM and phase 2 trials indicate that the combination of bevacizumab with standard-of-c...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2011-04, Vol.28 (4), p.334-340
Main Authors: Chinot, O. L., de La Motte Rouge, T., Moore, N., Zeaiter, A., Das, A., Phillips, H., Modrusan, Z., Cloughesy, T.
Format: Article
Language:English
Subjects:
Adult
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - adverse effects
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Alkylating - administration & dosage
Antineoplastic Agents, Alkylating - adverse effects
Bevacizumab
Brain Neoplasms - diagnosis
Brain Neoplasms - therapy
Cardiology
Clinical Protocols
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Dacarbazine - administration & dosage
Dacarbazine - adverse effects
Dacarbazine - analogs & derivatives
Endocrinology
Europe
Glioblastoma - diagnosis
Glioblastoma - therapy
Humans
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Pharmacology/Toxicology
Prognosis
Radiotherapy
Recurrence
Review
Rheumatology
Standard of Care
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite treatment with the current standard-of-care therapies, patients with newly diagnosed glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated activity in patients with recurrent GBM and phase 2 trials indicate that the combination of bevacizumab with standard-of-care therapy is feasible and active for patients with newly diagnosed GBM. Bevacizumab has been granted US approval for use as single-agent therapy for patients with progressive GBM following prior therapy, although it has not received approval for use in patients with GBM in Europe. Phase 3 studies have been initiated in patients with newly diagnosed GBM and are currently recruiting patients. We describe the protocol for the AVAglio phase 3 registration trial, which is designed to evaluate the efficacy and safety of combining bevacizumab with standard-of-care therapy in patients with newly diagnosed GBM.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-011-0007-3